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ABSTRACT: Background. Patients with head and neck cancer experi-
ence significant weight loss secondary to concurrent chemoradiotherapy
(CCRT). Using dual-energy X-ray absorptiometry (DEXA) scans, we char-
acterize total body composition changes during and after CCRT in order
to develop novel clinical care models that will improve the patient’s qual-
ity of life (QOL).
Methods. Sixty DEXA scans were obtained from 12 patients undergoing
CCRT for locally advanced squamous cell head and neck cancer. DEXAs
were performed at baseline, during treatment, completion of CCRT, and
then 1 and 2 months posttreatment.
Results. Mean weight loss by treatment end was 9.5 kg (10.2%;
p5 .0002). On average, lean body mass (LBM) decreased 10.2%
(p5 .001), and fat body mass (FBM) decreased 11.1% (p5 .001) during
CCRT. LBM began to normalize after completion of treatment, whereas
FBM continued to decline.
Conclusion. Substantial loss of muscle and FBM occurs in patients
undergoing CCRT for head and neck cancer. To prevent long-term
disability and QOL decline after curative CCRT, clinical care interven-
tions incorporating aggressive nutrition/exercise counseling are
needed. VC 2013 Wiley Periodicals, Inc. Head Neck 36: 1356–1362,
2014
KEY WORDS: total body composition, lean body mass, dual-energy
x-ray absorptiometry (DEXA), head and neck cancer,
chemoradiotherapy
INTRODUCTION
Changes in total body composition are common in
patients with cancer over the course of their treatment.
Cancers associated with adverse changes in body compo-
sition include pancreatic cancer, gastrointestinal cancers,
esophagogastric cancer, ovarian cancer, non-small cell
lung cancer, prostate cancer, breast cancer, and head and
neck cancer.1–9 Specific changes in total body composi-
tion tend to vary according to disease site and corre-
sponding treatment modality. Patients treated for breast
and prostate cancer can undergo sarcopenic obesity,
which results from a loss of muscle mass with an increase
in FBM.8,9 Patients with advanced cancers often experi-
ence cancer cachexia, which presents as a drastic loss in
muscle mass, with or without a corresponding loss of
FBM.10 Importantly, these changes in body composition
are known to be associated with decreased quality of life
(QOL) and worse overall prognosis.10–14
Patients with head and neck cancers often experience
significant unintentional weight loss that is multifactorial
in nature.15 It has been suggested that approximately 70%
of this weight loss arises from a loss of lean body mass
(LBM),6 and that this loss occurs despite appropriate
nutritional intake.16 Furthermore, this weight loss has
been shown to predict decreased overall survival in
patients with head and neck cancer.17,18 Therefore, in
order to improve QOL, physical functional status, and
potentially to improve overall prognosis, understanding
the changes that occur during and after head and neck
cancer treatment are essential to developing clinical mod-
els to help avert weight loss and changes in total body
composition in these patients.
To date, relatively little is known regarding the changes
in total body composition that occur during and after
treatment of head and neck cancer. We sought to charac-
terize changes in total body composition for patients
undergoing concurrent chemoradiation therapy (CCRT)
for locally advanced squamous cell head and neck cancer
using serial total body dual-energy X-ray absorptiometry
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(DEXA) scans. Because patients with head and neck can-
cer treated with CCRT often experience significant dehy-
dration, or changes in total fluid volume, we also sought to
correlate changes in total body composition with hydration
status through analysis of serum creatinine levels.
MATERIALS AND METHODS
Patient selection
Through an institutional review board approved pro-
spective study assessing the impact of exercise versus
usual care on changes in total body composition,
assessed using DEXA, for patients receiving CCRT for
locally advanced squamous cell head and neck cancer,
12 patients were accrued after giving informed consent.
Eligibility criteria included patients with American Joint
Committee on Cancer stage II to IV squamous cell head
and neck cancer receiving CCRT as first-line treatment
without surgery. Patients were not eligible if they had
active cardiopulmonary disease, dementia, acute medical
conditions unrelated to their head and neck cancer,
refused a percutaneous endoscopic gastrostomy tube for
nutrition as determined necessary by the treating physi-
cian, or were actively receiving physical therapy or exer-
cising 2 or more hours per day. All patients underwent a
preliminary nutritional assessment by a dietician before
initiation of treatment. Six patients received a percutane-
ous endoscopic gastrostomy (PEG) tube before initiation
of radiation therapy, and an additional 3 patients
received a PEG tube during radiation therapy for enteral
nutrition. Patients were monitored throughout their treat-
ment to ensure appropriate nutritional status with weekly
assessments during treatment in the radiation oncology
clinic. If a patient experienced >5% to 10% decrease in
body mass during the course of treatment, a nutritionist
was consulted. Eight patients met with a nutritionist at
least once after the initiation of treatment. Finally,
because no statistically significant differences in total
body composition were noted between the exercise and
usual care groups, we have combined their total body
composition analysis for the purposes of this study to
better understand these changes. All procedures were in
accordance with the ethical standards of the committee
on human experimentation of the institution or in accord
with the Helsinki Declaration of 1975 as revised in
1983.
Treatment and follow-up
Patients were treated with platinum-based CCRT for a
total of 7 weeks to a total dose of 70 Gy using intensity-
modulated radiation therapy (IMRT). Treatment was
administered to the primary tumor and bilateral necks.
Patients received IMRT at 2 institutions, with 9 patients
receiving treatment at the VA Ann Arbor Healthcare Sys-
tem, and 3 receiving treatment at the University of Michi-
gan. CCRT lasted 7 weeks. Patients were seen in follow-
up at 1 and 2 months post-CCRT. Serum creatinine was
routinely measured during and after CCRT to assess kid-
ney function before platinum-based chemotherapy and
serve as a means to assess fluid status.
Dual-energy X-ray absorptiometry
Total body DEXA scans were performed using an
iDXA whole body scanner (GE/Lunar Corp, Madison,
WI). All DEXA scans were performed at 1 institution
using the same scanner. DEXA scans were performed
with the patients in the supine position on the imaging
table and were acquired and processed in accord with the
manufacturer’s protocol. All patients received a DEXA
scan before the initiation of CCRT (week 0), during treat-
ment (between weeks 3 and 5), at the completion of treat-
ment (week 7), 4 weeks posttreatment (1-month follow-
up), and again at 7 to 8 weeks posttreatment (2-month
follow-up).
Statistical analysis
The cohort for the present analysis is a subset of a
larger cohort that is being accrued for a study assessing
the impact of exercise training on changes in total body
composition for patients receiving CCRT for locally
advanced head and neck cancer. Because the present anal-
ysis was only being performed on a small subset of the
cohort from the exercise training study, our goal was not
to assess the impact of exercise training, but rather to
characterize the overall changes in total body composition
for the 12 patients who had completed CCRT for locally
advanced head and neck cancer to date. These patients
had been randomized to receive either exercise training or
usual care. However, as no significant differences were
observed between patients assigned to exercise (n5 7)
versus those assigned to usual care (n5 5) regarding
mean decrease in LBM from baseline to the end of
CCRT (7.1 kg vs 4.6 kg; p5 .4) or mean decrease in
FBM over this same time period (3.0 kg vs 4.0 kg;
p5 .5), they were analyzed together. Mean cohort DEXA
values from different points in time were compared using
the paired samples t test. Pearson correlation coefficients
(r) were calculated to quantify correlation between varia-
bles of interest. All statistical analysis was performed
using MedCalc (v12.3.0.0, MedCalc Software, Maria-
kerke, Belgium).
RESULTS
Patient characteristics and changes in total body mass
All 12 patients had completed treatment at the time of
analysis. Eleven of 12 patients had been seen for their 2-
month posttreatment follow-up. Baseline and treatment-
related characteristics for all patients can be found in
Table 1. Median age of the cohort was 59 years at the
initiation of CCRT. All 12 patients were men, as the
majority was accrued from the Veteran’s Affairs (VA)
hospital. Ten of 12 patients had tumors arising in the oro-
pharynx, with the most common site being the base of
the tongue, and the majority of tumors were stage IVA
(75%). Changes in total body mass (TBM), LBM, and
FBM from baseline through treatment, to the 2-month
posttreatment follow-up can be found in Figure 1. Mean
pretreatment (baseline) weight was 93.0 kg (standard
deviation6 12.6 kg; 99.06 10.8 control vs 88.76 12.7
exercise), and mean pretreatment body mass index (BMI)
was 29.6 (63.7; 28.36 2.4 control vs 26.26 3.2
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exercise). Eleven of 12 patients lost weight over the 7-
week course of CCRT, 5 from the control arm and 6
from the exercise arm. Mean weight loss by the end of
treatment was 9.5 kg (10.2% decrease from baseline;
p5 .0002), resulting in a mean cohort weight of 83.5 kg
(610.1 kg; 90.46 6.5 control vs 78.66 9.5 exercise) at
the end of CCRT, and a mean BMI of 26.5 (62.8;
28.06 2.6 control vs 25.46 2.6 exercise). The largest
weight loss seen at the end of CCRT was 17.6 kg (exer-
cise arm). One patient in the exercise arm gained 1.9 kg
from the initiation of treatment to the end of treatment.
By the 2-month posttreatment follow-up, half of the
patients continued to have declines in their weight,
whereas the remaining had either stabilized or begun to
regain weight, resulting in a mean cohort weight of 81.1
kg (12.8% decrease from baseline; p5 .0003; 87.06 7.3
control vs 76.36 10.3 exercise) at the 2-month posttreat-
ment follow-up, and a mean BMI of 26.0 (62.8;
27.06 2.9 control vs 25.26 2.9 exercise).
Changes in lean body mass
Mean LBM at baseline was 59.2 kg (67.8 kg;
60.96 8.4 control vs 57.96 7.9 exercise), and accounted
for 64% of mean TBM. On average, patients lost 10.2%
(p5 .001) of their LBM over the course of CCRT, such
that the mean LBM at the end of treatment was 53.1 kg
(66.7 kg; 56.36 4.4 control vs 50.86 7.5 exercise).
Eleven of 12 patients lost LBM over the 7-week course
of CCRT, 4 from the control arm and 7 from the exercise
arm. Losses in LBM during treatment ranged from 0.9 kg
(exercise arm) to 11.3 kg (exercise arm). From treatment
end until the 2-month posttreatment follow-up, 8 of 12
patients began to regain LBM (3 from the control arm
and 5 from the exercise arm), resulting in a mean LBM
of 54.5 kg (67.7 kg; p5 .01; 57.16 7.4 control vs
52.36 7.9 exercise) at the 2-month posttreatment follow-
up, a 2.4% increase from the end of CCRT.
Changes in fat body mass
Mean fat body mass (FBM) at baseline was 30.6 kg
(67.5 kg; 34.76 5.8 control vs 27.66 7.5 exercise), and,
on average, accounted for 33% of TBM. On average,
patients lost 11.1% (p5 .001) of their FBM over the 7-
week course of therapy. Again, 11 of 12 patients lost
FBM during the course of CCRT. The mean FBM at the
end of treatment was 27.2 kg (66.4 kg; 30.76 5.8 control
vs 24.76 5.9 exercise). Unlike LBM, which began to
return toward baseline after CCRT, FBM continued to
decrease from the end of treatment until the 2-month
posttreatment follow-up for 11 of 12 patients, 4 from the
control arm and 7 from the exercise arm. By the 2-month
follow-up appointment, on average, patients had lost
22.9% (p5 .0003) of their baseline FBM. The loss in
FBM from baseline to the 2-month follow-up appointment
ranged from 2.3 kg (exercise arm) to 10.8 kg (control
arm). The majority of FBM was lost from the android
distribution. Overall, 7.8% (p5 .004) of FBM was lost
from the android distribution, whereas only 3.3%
(p5 .01) was lost from the gynoid distribution.
Changes in total body mass composition
At baseline, mean total body composition was 64%
LBM, 33% FBM, and 3% bone mass (Figure 2). Even
though the weight loss continued over the 2 months after
completion of CCRT, the total body composition ratio
remained relatively unchanged over the course of treat-
ment. At the end of treatment, the composition of TBM
was nearly identical, with LBM accounting for 64% of
TBM, FBM accounting for 32%, and bone constituting
4%. By the 2-month posttreatment follow-up, there was
once again very little variation in total body composition,
with TBM being 67% LBM, 29% FBM, and 4% bone
mass. A larger percentage of TBM lost over the course of
CCRT was from LBM as compared to FBM (64% vs
36%, respectively). By the 1-month follow-up appoint-
ment, the contribution to TBM loss of LBM loss and
FBM loss were quite similar (51% vs 49%, respectively).
TABLE 1. Patient baseline and treatment related characteristics.
Characteristic Mean (6SD) No. of patients (%)
Age, y 57.0 (68.1)
Weight, kg 93.0 (612.6)
BMI 29.6 (63.7)
LBM, kg 59.2 (67.8)
FBM, kg 30.6 (67.5)
Stage
III 2 (16.7)
IVA 9 (75.0)
IVB 1 (8.3)
Tumor site
Base of tongue 6 (50.0)
Tonsil 4 (33.3)
Aryepiglottic fold 1 8.3)
Unknown primary 1 (8.3)
Treatment modality
CCRT 12 (100.0)
IMRT dose, Gy 70.0 (60.0)
RT treatment target
Primary tumor1 bilateral neck 12 (100.0)
Receiving PEG
Total 9 (75.0)
At baseline 6 (50.0)
During treatment 3 (25.0)
Abbreviations: BMI, body mass index; LBM, lean body mass; FBM, fat body mass; CCRT, con-
current chemoradiotherapy; IMRT, intensity-modulated radiotherapy; RT, radiotherapy; PEG,
percutaneous endoscopic gastrostomy.
FIGURE 1. Percent change in total, lean, and fat body mass from
baseline through 2-month posttreatment follow-up.
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At the 2-month posttreatment follow-up, FBM loss con-
tributed a larger percentage to TBM loss than LBM loss
(60% vs 40%, respectively).
Relationship of changes in lean and fat body mass to
patient hydration status
Through the course of the study, it was noted that
patients who appeared to be clinically dehydrated because
of treatment-related toxicity, also had changes noted on
DEXA measurements of LBM. To better assess this rela-
tionship, we correlated serum creatinine obtained around
the same time of DEXA scans to changes in LBM.
Mean baseline serum creatinine was 1.0 mg/dL (range,
0.7–1.2 mg/dL). Mean serum creatinine increased to 1.5
mg/dL (range, 0.7–3.8 mg/dL; p5 .07) by the end of
CCRT, and decreased to a mean value of 1.3 mg/dL
(range, 0.8–2.3 mg/dL; p5 .2) by the 2-month posttreat-
ment follow-up. DEXA measurements of LBM and serum
creatinine were inversely associated (r520.3; p5 .04),
however, such an association did not exist between FBM
and serum creatinine (r520.13; p5 .4). Graphic repre-
sentation of the relationship between changes in serum
creatinine, LBM, and FBM can be found in Figure 3. The
decrease in LBM seen over the course of treatment was
inversely paralleled by an increase in serum creatinine.
As LBM began to return toward baseline levels after
treatment, serum creatinine began to normalize as well.
This inverse relationship was not present for the changes
in FBM, as FBM decreased at a nearly continuous rate
from baseline to the 2-month posttreatment follow-up
independently from changes in serum creatinine.
DISCUSSION
Using serial DEXA scans, we were able to characterize
changes in total body composition during and after treat-
ment for a group of patients receiving CCRT for locally
advanced head and neck cancer. Nearly the entire cohort
experienced significant weight loss from the initiation of
CCRT to the end of treatment, with a mean weight loss
over the 7-week course of treatment of 9.5 kg. Of this
weight loss, two-thirds was from a loss in LBM, and one-
third was from a loss in FBM. Mean BMI declined from
29.6 to 26.5 during CCRT. After completion of CCRT,
the majority of patients began to regain LBM; however,
nearly all continued to lose FBM through the 2-month
posttreatment follow-up period. Patients lost the majority
of their FBM from the android distribution. BMI also
continued to decline, with a mean BMI of 26.0 by the 2-
month posttreatment follow-up. The finding that FBM
continued to decline post-CCRT may somewhat be
accounted for by the fact that, on average, patients were
overweight per BMI weight stratification at baseline. Dur-
ing CCRT, LBM loss exceeded FBM loss; however, the
proportion of LBM and FBM loss compared to baseline
LBM and FBM were similar. By treatment end, patients
had lost 10.3% of their baseline LBM, and 11.1% of their
baseline FBM. Thus, although LBM was the largest con-
tributor to total mass lost at the end of treatment, this
may be a reflection of the fact that LBM contributed
more to TBM at baseline than FBM. This is supported by
our finding that TBM composition was stable throughout
our study, as the percentage contribution to TBM of
LBM, FBM, and bone mass varied little from baseline to
the 2-month posttreatment follow-up. LBM constituted
FIGURE 2. (A) Percent of relative total body composition at base-
line, (B) percent of relative total body composition at the end of
concurrent chemoradiotherapy (CCRT), and (C) percent of relative
total body composition at the 2-month posttreatment follow-up.
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64% to 67% of TBM at baseline, at the end of CCRT,
and at the 2-month posttreatment follow-up.
Our findings regarding changes in TBM and LBM for
patients undergoing CCRT for locally advanced head and
neck cancer are comparable to those reported by Silver et
al,6 who reported a 10.1 kg loss in TBM at 1-month post-
treatment, with 71.7% of this loss accounted for by loss
in LBM. We found a slightly greater loss in TBM with
less contribution of LBM in the present analysis (12.0 kg
loss in TBM, 49% LBM). A second difference between
our findings and those reported by Silver et al6 is that
patients in our cohort began to regain LBM after comple-
tion of CCRT, and this was evident at both the 1-month
and 2-month posttreatment follow-ups, whereas Silver et
al6 reported a continuous linear decline in LBM at the 1-
month posttreatment follow-up. Silver et al6 only reported
a 1-month posttreatment follow-up, and, thus, we cannot
compare our findings at 2-months posttreatment follow-
up. It is possible that differences in our findings have
underestimated the degree of LBM loss because of 7
patients receiving exercise training during and after
CCRT; however, there were no statistically significant
differences in changes of total body composition between
this group and the control group, although this is not sur-
prising given the overall small sample size.
Another finding in our study was the inverse correlation
between LBM loss and serum creatinine during and after
CCRT. Several plausible explanations exist for this corre-
lation. First, patients undergoing CCRT for head and neck
cancer often become significantly dehydrated.19 This vol-
ume depletion can lead to prerenal azotemia, which can
result in increased serum creatinine.20 Furthermore, water
constitutes a large percentage of LBM. Mean LBM
reached its nadir at the end of treatment, which corre-
sponded with the greatest mean increase in serum creati-
nine. After treatment, when one would expect volume
status to improve, LBM began to rebound and serum cre-
atinine levels began to normalize. Thus, a portion of the
inverse correlation between serum creatinine and LBM
may merely be a reflection of hydration status. Another
explanation for the rise in serum creatinine during treat-
ment is secondary to renal toxicity from the platinum-
based chemotherapy regimen.21 This could explain the
acute rise in creatinine during treatment and why serum
creatinine began to normalize post-CCRT, but mean base-
line creatinines were never reached.
The possibility that at least a portion of LBM loss
observed on DEXA may merely be a reflection of fluid
volume status raises the question as to whether DEXA is
the optimal tool to measure body composition in patients
with cancer with fluctuating fluid status, and who during
treatment can be dehydrated or hypovolemic.22 Going et
al23 assessed the ability of DEXA to detect changes in
body composition in 17 patients undergoing a
FIGURE 3. (A) Changes in mean lean body mass versus mean serum creatinine from baseline through the 2-month posttreatment follow-up. (B)
Changes in mean fat body mass versus mean serum creatinine (Cr) from baseline through the 2-month posttreatment follow-up.
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dehydration-rehydration protocol that induced small
changes in body composition. They concluded that
although DEXA seemed to provide accurate estimates of
changes in body water during the dehydration-rehydration
protocol that it was limited in determining whether these
changes occurred in the lean or fat components of TBM.
Thus, although these results show potential for DEXA in
detecting small changes in hydration status, less is known
regarding the overall accuracy of DEXA in patients
undergoing large changes in volume status, such as in
patients with head and neck cancer undergoing treatment.
More recently, CT has been used as a means of accu-
rately assessing LBM in patients with cancer.24,25 CT
offers a benefit of convenience for the patient and limits
additional tests as most patients with cancer undergo rou-
tine imaging with either CT or MRI before and after
treatment. Future work is needed to define the ideal
modality for measuring changes in LBM for patients with
cancer undergoing therapy that may result in significant
changes in overall hydration status. A direct comparison
between CT and DEXA in such a patient group may help
to shed more light on this issue.
Seventy-five percent of the patients in this study
received a PEG tube before or during treatment (50%
before and 25% during) for nutritional support, and all
patients received nutritional guidance from a dietician
before the initiation of treatment. The proportion of our
patients receiving a PEG tube before or during treatment
are greater than those recently reported by Locher et al26
through analysis of the Surveillance, Epidemiology, and
End Results database, in which 47.8% of patients treated
for head and neck cancer with radiotherapy received a
PEG tube before or during treatment (30% before and
70% during). The higher use of PEG tube placement in
our study is consistent with findings by Murphy et al27
that showed that PEG tube placement occurs more com-
monly in academic centers as compared to community
settings. Despite the majority of patients receiving nutri-
tional supplementation with a PEG tube, our study shows
that patients with head and neck cancer receiving CCRT
experience significant TBM, LBM, and FBM losses.
Importantly, weight loss during treatment of advanced
head and neck cancer has been shown to be independ-
ently associated with decreased overall survival.18 There-
fore, identifying means by which to diminish this weight
loss is of utmost clinical importance. A combination of
extended nutritional counseling and or supplementation
with combined exercise training may help mitigate the
loss of LBM and fat during and after CCRT.28 Exercise
in cancer survivors has been shown to improve function-
ality and QOL in patients undergoing treatment for can-
cer.29,30 A recent Cochrane review found that exercise
training during cancer treatment may improve overall
health-related QOL, and that increasing intensities of
exercise were related to improved benefit.30 Furthermore,
in patients with breast and prostate cancers, exercise
training has been shown to increase or preserve
LBM.31,32 Nutritional interventions are also recommended
for patients with head and neck cancer. A recent system-
atic review supported the use of individualized dietary
counseling in combination with dietary supplementation
for patients with head and neck cancer treated with radio-
therapy.33 Therefore, a combined exercise and nutritional
program may be able to provide the same benefits for
patients undergoing CCRT for locally advanced head and
neck cancer. The challenge becomes identifying the ideal
balance between nutritional support and exercise, as well
as the timing of these interventions, that provides optimal
patient outcomes. A recent review of Radiation Therapy
Oncology Group 90-03 identified an association between
nutritional support before initiation of treatment and
worse outcomes after treatment, even when controlling
for stage and performance status.34 Although these find-
ings are controversial and require validation, they do
highlight that further work is needed to identify the pre-
ferred timing and method of nutritional support for
patients receiving treatment for head and neck cancer.
Similar efforts are needed to identify the ideal timing and
mode of exercise training, and to better define the inter-
play between exercise training and nutritional support.
In conclusion, we show that patients with locally
advanced squamous cell head and neck cancer lose a sig-
nificant amount of TBM, LBM, and FBM while under-
going CCRT. LBM begins to return toward baseline after
the completion of treatment for most patients, whereas
FBM loss continued through the 2-month posttreatment
follow-up. Changes in LBM as measured by DEXA were
inversely related to changes in serum creatinine suggest-
ing that in patients prone to dehydration, DEXA scan
measurements of total body composition may lead to
inaccuracies. However, the loss of LBM in patients with
head and neck cancer undergoing CCRT is apparent and
its implications regarding patient’s functional status and
QOL need to be studied further. Exercise training during
and after cancer treatment has been effective in negating
LBM loss in other patients with cancer, and may offer an
opportunity to do the same for patients with head and
neck cancer, thereby helping to improve patient QOL and
outcomes.
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